Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Coates

Showing results (391-400 of 574) with videos related to

Pageof 58
Sort By:
Rheumatology (Oxford, England)|January 13, 2024
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Rheumatology and Therapy|July 17, 2023
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid ArthritisGerd R Burmester, Laura C Coates, Stanley B Cohen, et al.
Lancet (London, England)|October 5, 2015
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trialLaura C Coates, Anna R Moverley, Lucy McParland, et al.
Rheumatology (Oxford, England)|October 19, 2019
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)Ana-Maria Orbai, Alexis Ogdie, Laure Gossec, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Nature Plants|March 14, 2023
DELLA functions evolved by rewiring of associated transcriptional networksAsier Briones-Moreno, Jorge Hernández-García, Carlos Vargas-Chávez, et al.
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Arthritis Care & Research|September 12, 2013
Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasoundJane E Freeston, Laura C Coates, Jackie L Nam, et al.
Arthritis Care & Research|May 26, 2017
Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled TrialJohn L O'Dwyer, David M Meads, Claire T Hulme, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Pageof 58

Showing results (391-400 of 574) with videos related to

Sort By:
Pageof 58
Rheumatology (Oxford, England)|January 13, 2024
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Rheumatology and Therapy|July 17, 2023
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid ArthritisGerd R Burmester, Laura C Coates, Stanley B Cohen, et al.
Lancet (London, England)|October 5, 2015
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trialLaura C Coates, Anna R Moverley, Lucy McParland, et al.
Rheumatology (Oxford, England)|October 19, 2019
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)Ana-Maria Orbai, Alexis Ogdie, Laure Gossec, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Nature Plants|March 14, 2023
DELLA functions evolved by rewiring of associated transcriptional networksAsier Briones-Moreno, Jorge Hernández-García, Carlos Vargas-Chávez, et al.
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Arthritis Care & Research|September 12, 2013
Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasoundJane E Freeston, Laura C Coates, Jackie L Nam, et al.
Arthritis Care & Research|May 26, 2017
Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled TrialJohn L O'Dwyer, David M Meads, Claire T Hulme, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Pageof 58